查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1516708

高三酸甘油脂血症 (HTG) 的全球市场管道

Global Hypertriglyceridemia Market Pipeline
出版日期: | 出版商: Inkwood Research | 英文 295 Pages | 商品交期: 2-3个工作天内

价格

主要发现

高三酸甘油脂血症（HTG）是一种以血液中三酸甘油酯含量高为特征的疾病。三酸甘油酯是脂肪的一种，从饮食中获取并由身体产生。三酸甘油酯水平升高会使您面临心臟病和中风等心血管疾病的风险。

此外，高三酸甘油脂血症（HTG）与肥胖、不受控制的糖尿病、甲状腺功能减退、肝臟和肾臟疾病以及某些遗传性疾病有关。高脂肪饮食、过度饮酒和缺乏运动等生活习惯会增加三酸甘油酯水平。治疗包括饮食改变、体重管理、规律运动和必要时药物治疗。

市场洞察

全球高三酸甘油脂血症（HTG）市场的关键成长因素

  • 提高对高三酸甘油脂血症（HTG）的认识
  • 高三酸甘油脂血症 (HTG) 盛行率增加
  • 扩大治疗选择

高三酸甘油酯血症 (HTG) 可以透过改变生活方式来控制，例如减少脂肪和碳水化合物的摄取、限制饮酒、戒烟和定期运动。

此外，他汀类药物和贝特类药物等治疗方法已被用来降低三酸甘油酯（TG）水平。目前，治疗高三酸甘油脂血症（HTG）的主要药物是他汀类药物和贝特类药物。然而，有些患者可能不适合这些治疗或可能对这些治疗没有反应。

为了弥补这一差距，各公司正在努力开发新的治疗方法，旨在更有效地降低血液中的三酸甘油酯并减轻高三酸甘油酯血症 (HTG) 的影响。特别是，针对载脂蛋白 C-III 和 ANGPTL 的方法已被广泛探索。

同时，基于载脂蛋白C-III的新药也显示出可喜的结果，预计将在不久的将来上市。这种创新疗法的推出有可能显着推进 HTG 管理，并为对目前治疗有抗药性的患者提供更好的选择。

全球高三酸甘油脂血症（HTG）市场的主要成长限制因素

  • 开发新疗法遇到挫折

高三酸甘油脂血症治疗药物和产品的开发在早期和后期的临床试验中失败率很高。

同时，Pfizer和 Ionis 最近停止了其 III 期药物 Vaupanorsen，因为 II 期结果不足以证明继续临床开发计划的合理性。

同样，其他製药公司儘管早期结果令人鼓舞，但在后期临床试验中却面临重大挫折。

新药开发过程中的任何阶段都可能失败。早期临床试验的结果不一定代表后期临床试验的结果，根据患者群的不同，后期临床试验的结果可能会大不相同。因此，新兴疗法的这些挫折是市场成长的主要障碍。

  • 获得批准的障碍
  • 生活方式和饮食改变的建议
  • 临床试验结果不理想；

高三酸甘油脂血症 (HTG) | 疾病概述

  • 介绍
  • 症状
  • 原因

高三酸甘油脂血症（HTG）的病因可分为遗传性疾病（原发性疾病）和其他疾病引起的继发性疾病。

脂蛋白脂肪酶(LPL) 缺乏症和载脂蛋白(Apo) C-II 缺乏症是两种独特的遗传性疾病，在婴儿期表现为乳糜微粒血症综合征，并导致儿童期高三酸甘油酯血症。在成人中，空腹浓度极高的乳糜微粒、极低密度脂蛋白 (VLDL) 碎片通常表示有严重的 HTG。

HTG 最常见的继发性原因包括肥胖、未经治疗的糖尿病、饮酒、怀孕和各种药物治疗。许多这些次要原因与胰岛素反应异常有关。

  • 诊断

高三酸甘油脂血症（HTG）透过空腹血脂检查来诊断。根据National Cholesterol Education Program Adult Treatment Panel III（NCEP ATP III）指南，HTG 可以是轻度(150-199 mg/dL)、高(200-499 mg/dL) 或非常高(>=500 mg/dL) 。

当三酸甘油酯高于 400 mg/dL 时，通常使用 Friedewald 公式估算 LDL-C 值，但这可能会低估 LDL-C。或者，可以考虑直接测量非 HDL-C（总胆固醇减去 HDL 胆固醇）或 LDL-C。

评估 LDL 大小和密度不被认为有利于 HTG 心血管事件的管理。ApoB 和 Lp(a) 水准有助于评估心血管风险。治疗方法包括有效降低 Apo B 水平，烟碱酸和雌激素可以降低 Lp(a)。然而，没有确切的证据显示降低 Lp(a) 可以预防动脉粥状硬化性心血管疾病。

Lp(a) 水平升高与早发性心血管疾病相关，高 Lp(a) 水平证明积极的 LDL 管理是合理的。由于胰岛素阻抗，肝脂肪变性或非酒精性脂肪性肝炎 (NASH) 常与高血压并存。肝功能测试中转氨酶升高建议进一步评估，包括肝臟超音波检查。

  • 治疗

竞争考虑

全球高三酸甘油脂血症 (HTG) 市场的主要参与者

  • Arrowhead Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • 89Bio Inc
  • Rivus Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • MediciNova Inc
  • Matinas BioPharma Holdings Inc

我们提供 10% 免费客製化和 3 个月的分析师支援。

常见问题（FAQ）：

  • 儿童会罹患高三酸甘油脂血症（HTG）吗？

答：是的，儿童有可能患有高三酸甘油脂血症 (HTG)。高三酸甘油脂血症 (HTG) 可能会发生，特别是如果您有血脂异常家族史、久坐的生活方式或不健康的饮食。早期发现和介入对于预防长期健康併发症非常重要。

  • 高三酸甘油脂血症和高胆固醇血症一样吗？

答：不，虽然它们是相关的，但高三酸甘油酯血症特指血液中三酸甘油酯水平升高。高胆固醇血症是指LDL（低密度脂蛋白）胆固醇含量过高，俗称坏胆固醇，也是心血管疾病的危险因子。

目录

第一章简介

第 2 章 高三酸甘油脂血症 (HTG)：概述

第三章概述

  • 介绍
  • 高三酸甘油脂血症 (HTG) 的分类
  • 富含三酸甘油酯的脂蛋白的代谢
  • 病因和危险因子
  • 临床症状
  • 诊断
    • 鑑别诊断
  • 治疗和管理

第四章市场动态

  • 主要驱动因素
    • 提高对高三酸甘油脂血症（HTG）的认识
    • 高三酸甘油脂血症 (HTG) 盛行率增加
    • 扩大治疗选择
  • 主要限制因素
    • 新疗法开发的回归
    • 获得监管部门批准的障碍
    • 改善生活习惯和饮食习惯的建议
    • 临床试验结果不理想

第五章管道处理

  • 目前管道概述
  • 比较分析：各阶段产品

第六章治疗评估：有效的产品

  • 依给药途径评价
  • 依阶段和给药途径进行评价
  • 依分子类型评估
  • 依阶段/分子类型评估

第七章 后期产品（第三期）

  • 比较分析
  • OLEZARSEN：IONIS PHARMACEUTICALS INC
    • 产品描述
    • 研究与开发
  • MND 2119：MOCHIDA PHARMACEUTICAL
    • 产品描述
    • 研究与开发
  • PEGOZAFERMIN：89BIO
    • 产品描述
    • 研究与开发
    • 安全性/有效性

第八章 中期产品（二期）

  • 比较分析
  • PLOZASIRAN：ARROWHEAD PHARMACEUTICALS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • EVINACUMAB：REGENERON PHARMACEUTICALS
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • SEFA-1024：NORTHSEA THERAPEUTICS
    • 产品描述
    • 研究与开发
  • HU-6：RIVUS PHARMACEUTICALS
    • 产品描述
  • MAT-9001：MATINAS BIOPHARMA
    • 产品描述
    • 研究与开发
    • 安全性/有效性
  • MN-001：MEDICINOVA
    • 产品描述
    • 研究与开发
  • INV-202：NOVO NORDISK
    • 产品描述
    • 研究与开发
    • 安全性/有效性
    • 产品开发活动
  • HTD1801：HIGHTIDE BIOPHARMA
    • 产品描述
  • MET-3：NUBIYOTA
    • 产品描述

第九章 早期产品（I/II期）

  • 比较分析
  • MAR-001：MAREA THERAPEUTICS
    • 产品描述
    • 研究与开发

第 10 章早期产品（第一阶段）

  • 比较分析
  • LY 3875383：ELI LILLY AND COMPANY
    • 产品描述
    • 研究与开发
  • VSA-003：VISIRNA THERAPEUTICS
    • 产品描述
    • 研究与开发
  • GC 304：GENECRADLE THERAPEUTICS
    • 产品描述
    • 研究与开发
  • TLC-2716：ORSOBIO INC
    • 产品描述
    • 研究与开发
    • 产品开发活动
  • LIPISENSE：LIPIGON PHARMACEUTICALS
    • 产品描述
    • 研发内容
    • 安全性/有效性

第十一章 临床前阶段产品

  • 比较分析
  • STP125G：SIRNAOMICS
    • 产品描述
  • IMBP 001：IMETABOLIC BIOPHARMA
    • 产品描述
    • 产品/开发活动
  • STP251G：SIRNAOMICS
    • 产品描述
  • STP237G：SIRNAOMICS
    • 产品描述
  • SEFA 6131：NORTHSEA THERAPEUTICS
    • 产品描述
  • VK1430：VIKING THERAPEUTICS
    • 产品描述

第 12 章发现阶段产品

  • 比较分析
  • ANGPTL3/8 ANTIBODY PROGRAM：KYTTARO
    • 产品描述
    • 产品开发活动
  • IMBP 150：IMETABOLIC BIOPHARMA
    • 产品描述

第 13 章非活跃产品

  • 比较分析

第十四章 策略发展

  • 合併/收购
  • 合伙/合约

第15章未满足的需求

Product Code: 90768

KEY FINDINGS

Hypertriglyceridemia (HTG) is a condition marked by high triglyceride levels in the blood. Triglycerides, a type of fat, are sourced from dietary intake and produced by the body. Elevated triglyceride levels pose risks for cardiovascular diseases like heart disease and stroke.

Additionally, hypertriglyceridemia correlates with obesity, poorly controlled diabetes, hypothyroidism, liver or kidney disease, and specific genetic disorders. Lifestyle factors such as high-fat diets, excessive alcohol consumption, and physical inactivity can elevate triglycerides. Treatment includes dietary changes, weight management, regular exercise, and medication as necessary.

MARKET INSIGHTS

Key growth enablers of the global hypertriglyceridemia market:

  • Heightened awareness of hypertriglyceridemia
  • Growing prevalence of hypertriglyceridemia
  • Widening range of treatment options

Hypertriglyceridemia can be managed through lifestyle changes such as reducing fat and carbohydrate intake, limiting alcohol, quitting smoking, and regular exercise.

Moreover, therapeutic approaches such as statins and fibrates are employed to reduce triglyceride (TG) levels. Currently, statins and fibrates represent the main pharmacological therapies for hypertriglyceridemia (HTG). However, certain patients may be ineligible for or may not respond to these treatments.

To address this gap, companies are developing new therapeutic approaches aimed at more effectively reducing triglycerides in the bloodstream and mitigating the impact of HTG. Notably, approaches targeting apolipoprotein C-III and ANGPTL are being extensively explored.

In parallel, emerging drugs based on apolipoprotein C-III have shown promising results and are expected to reach the market in the near future. The anticipated launch of these innovative treatments could significantly advance HTG management, providing improved options for patients resistant to current therapies.

Key growth restraining factors of the global hypertriglyceridemia market:

  • Setbacks in new treatment development

Drug and product development for HTG is facing a high rate of clinical trial failures, occurring in the early phases and the later stages of development.

In line with this, Pfizer and Ionis recently discontinued the Phase III drug Vupanorsen after Phase II results did not justify continuing the clinical development program.

Similarly, other pharmaceutical companies have faced significant setbacks in late-stage clinical trials, even after promising outcomes in earlier stages.

Failures can arise at any stage during the development of emerging drugs. Initial clinical trial outcomes are not always indicative of later-stage results, and they can vary significantly across different patient cohorts. Hence, these setbacks with emerging therapies represent a significant barrier to market growth.

  • Obstacles in gaining regulatory approval
  • Recommendation for lifestyle and dietary changes
  • Suboptimal results from clinical trials

Hypertriglyceridemia | Disease Overview

  • Introduction
  • Symptoms
  • Causes

The causes of hypertriglyceridemia can be divided into genetically based disorders (primary disorders) and secondary disorders caused by other conditions.

Lipoprotein lipase (LPL) deficiency and Apolipoprotein (Apo) C-II deficiency are two well-characterized genetic forms of HTG occurring in infancy as chylomicronemia syndromes, leading to early childhood HTG. In adults, severe HTG is often indicated by extremely high fasting levels of chylomicrons, very low-density lipoproteins (VLDL), and remnants.

Among the most common secondary causes of HTG are obesity, untreated diabetes mellitus, alcohol consumption, pregnancy, and various medications. Many of these secondary causes are associated with abnormalities in insulin responsiveness.

  • Diagnosis

Hypertriglyceridemia (HTG) is diagnosed via a fasting lipid panel. As per the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines, HTG is classified based on triglyceride levels: mild (150-199 mg/dL), high (200-499 mg/dL), and very high (>=500 mg/dL).

When triglycerides exceed 400 mg/dL, LDL-C levels are often estimated using the Friedewald equation, which may underestimate LDL-C. Alternatively, non-HDL-C (total cholesterol minus HDL cholesterol) or direct LDL-C measurement can be considered.

Assessing LDL size or density is not considered beneficial for managing cardiovascular events in HTG. Apo B and Lp(a) levels may assist in assessing cardiovascular risk. Therapeutic options include effectively lowering Apo B levels, while niacin and estrogen may reduce Lp(a). However, evidence does not conclusively support that reducing Lp(a) prevents atherosclerotic cardiovascular disease.

High Lp(a) levels correlate with premature cardiovascular disease, warranting aggressive LDL management when Lp(a) levels are elevated. Hepatic steatosis or non-alcoholic steatohepatitis (NASH) often coexists with HTG due to insulin resistance. Elevated aminotransferases in liver function tests suggest further evaluation, including liver ultrasound.

  • Treatment

COMPETITIVE INSIGHTS

Major players in the global hypertriglyceridemia market:

  • Arrowhead Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • 89Bio Inc
  • Rivus Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • MediciNova Inc
  • Matinas BioPharma Holdings Inc

Arrowhead Pharmaceuticals Inc (Arrowhead) is a biotechnology company specializing in the development and commercialization of gene silencing therapeutics. The company employs RNA chemistries and its proprietary TRiM platform to target and silence genes that cause diseases. Arrowhead's product pipeline includes ARO-AAT, GSK4532990, ARO-ANG3, ARO-APOC3, ARO-PNPLA3, ARO-C3, ARO-ENaC2, ARO-MUC5AC, ARO-RAGE, ARO-COV, ARO-DUX4, ARO-MMP7, JNJ-3989, ARO-SOD1, HZN-457, and Olpasiran. These therapeutics address various conditions, including hypertriglyceridemia, dyslipidemia, facioscapulohumeral muscular dystrophy, complement-mediated diseases, and muco-obstructive or inflammatory pulmonary conditions. They also target liver disease, idiopathic pulmonary fibrosis, gout, cardiovascular disease, and chronic hepatitis B. Moreover, Arrowhead operates laboratory facilities in San Diego, California, and Madison, Wisconsin, with its headquarters located in Pasadena, California, United States.

The company is developing Plozasiran, a drug designed to reduce the production of Apolipoprotein C-III (apoC-III). ApoC-III is a key component of triglyceride-rich lipoproteins (TRLs) such as VLDL and chylomicrons, and it is fundamental in regulating triglyceride metabolism. The company anticipates that reducing hepatic production of apoC-III could potentially decrease VLDL synthesis and assembly, enhance the breakdown of TRLs, and improve the clearance of VLDL and chylomicron remnants. Plozasiran is presently undergoing Phase II clinical trials for treating severe hypertriglyceridemia.

We Offer 10% Free Customization and 3 Months Analyst Support

Frequently Asked Questions (FAQs):

  • Can children have hypertriglyceridemia?

A: Yes, children can also develop hypertriglyceridemia, especially if they have a family history of lipid disorders or if they lead sedentary lifestyles and consume unhealthy diets. Early detection and intervention are crucial to prevent long-term health complications.

  • Is hypertriglyceridemia the same as high cholesterol?

A: No, while related, hypertriglyceridemia specifically denotes elevated levels of triglycerides in the bloodstream. High cholesterol typically refers to elevated levels of LDL (low-density lipoprotein) cholesterol, commonly known as bad cholesterol, which also poses a risk factor for cardiovascular disease.

TABLE OF CONTENTS

1. INTRODUCTION TO THE REPORT

2. HYPERTRIGLYCERIDEMIA: SUMMARY

3. OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. CLASSIFICATION OF HYPERTRIGLYCERIDEMIA (HTG)
  • 3.3. METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
  • 3.4. ETIOLOGY AND RISK FACTORS
  • 3.5. CLINICAL SIGNS AND SYMPTOMS
  • 3.6. DIAGNOSIS
    • 3.6.1. DIFFERENTIAL DIAGNOSIS
  • 3.7. TREATMENT AND MANAGEMENT

4. MARKET DYNAMICS

  • 4.1. KEY DRIVERS
    • 4.1.1. HEIGHTENED AWARENESS OF HYPERTRIGLYCERIDEMIA
    • 4.1.2. GROWING PREVALENCE OF HYPERTRIGLYCERIDEMIA
    • 4.1.3. WIDENING RANGE OF TREATMENT OPTIONS
  • 4.2. KEY RESTRAINTS
    • 4.2.1. SETBACKS IN NEW TREATMENT DEVELOPMENT
    • 4.2.2. OBSTACLES IN GAINING REGULATORY APPROVAL
    • 4.2.3. RECOMMENDATION FOR LIFESTYLE AND DIETARY CHANGES
    • 4.2.4. SUBOPTIMAL RESULTS FROM CLINICAL TRIALS

5. PIPELINE THERAPEUTICS

  • 5.1. CURRENT PIPELINE OVERVIEW
  • 5.2. COMPARATIVE ANALYSIS: PRODUCTS IN VARIOUS PHASES

6. THERAPEUTIC ASSESSMENT: ACTIVE PRODUCTS

  • 6.1. EVALUATION BY ROUTE OF ADMINISTRATION
  • 6.2. EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • 6.3. EVALUATION BY MOLECULE TYPE
  • 6.4. EVALUATION BY STAGE AND MOLECULE TYPE

7. LATE-STAGE PRODUCTS (PHASE III)

  • 7.1. COMPARATIVE ANALYSIS
  • 7.2. OLEZARSEN: IONIS PHARMACEUTICALS INC
    • 7.2.1. PRODUCT DESCRIPTION
    • 7.2.2. RESEARCH AND DEVELOPMENT
  • 7.3. MND 2119: MOCHIDA PHARMACEUTICAL
    • 7.3.1. PRODUCT DESCRIPTION
    • 7.3.2. RESEARCH AND DEVELOPMENT
  • 7.4. PEGOZAFERMIN: 89BIO
    • 7.4.1. PRODUCT DESCRIPTION
    • 7.4.2. RESEARCH AND DEVELOPMENT
    • 7.4.3. SAFETY AND EFFICACY

8. MID-STAGE PRODUCTS (PHASE II)

  • 8.1. COMPARATIVE ANALYSIS
  • 8.2. PLOZASIRAN: ARROWHEAD PHARMACEUTICALS
    • 8.2.1. PRODUCT DESCRIPTION
    • 8.2.2. RESEARCH AND DEVELOPMENT
    • 8.2.3. SAFETY AND EFFICACY
  • 8.3. EVINACUMAB: REGENERON PHARMACEUTICALS
    • 8.3.1. PRODUCT DESCRIPTION
    • 8.3.2. RESEARCH AND DEVELOPMENT
    • 8.3.3. SAFETY AND EFFICACY
  • 8.4. SEFA-1024: NORTHSEA THERAPEUTICS
    • 8.4.1. PRODUCT DESCRIPTION
    • 8.4.2. RESEARCH AND DEVELOPMENT
  • 8.5. HU-6: RIVUS PHARMACEUTICALS
    • 8.5.1. PRODUCT DESCRIPTION
  • 8.6. MAT-9001: MATINAS BIOPHARMA
    • 8.6.1. PRODUCT DESCRIPTION
    • 8.6.2. RESEARCH AND DEVELOPMENT
    • 8.6.3. SAFETY AND EFFICACY
  • 8.7. MN-001: MEDICINOVA
    • 8.7.1. PRODUCT DESCRIPTION
    • 8.7.2. RESEARCH AND DEVELOPMENT
  • 8.8. INV-202: NOVO NORDISK
    • 8.8.1. PRODUCT DESCRIPTION
    • 8.8.2. RESEARCH AND DEVELOPMENT
    • 8.8.3. SAFETY AND EFFICACY
    • 8.8.4. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 8.9. HTD1801: HIGHTIDE BIOPHARMA
    • 8.9.1. PRODUCT DESCRIPTION
  • 8.10. MET-3: NUBIYOTA
    • 8.10.1. PRODUCT DESCRIPTION

9. EARLY-STAGE PRODUCTS (PHASE I/II)

  • 9.1. COMPARATIVE ANALYSIS
  • 9.2. MAR-001: MAREA THERAPEUTICS
    • 9.2.1. PRODUCT DESCRIPTION
    • 9.2.2. RESEARCH AND DEVELOPMENT

10. EARLY-STAGE PRODUCTS (PHASE I)

  • 10.1. COMPARATIVE ANALYSIS
  • 10.2. LY 3875383: ELI LILLY AND COMPANY
    • 10.2.1. PRODUCT DESCRIPTION
    • 10.2.2. RESEARCH AND DEVELOPMENT
  • 10.3. VSA-003: VISIRNA THERAPEUTICS
    • 10.3.1. PRODUCT DESCRIPTION
    • 10.3.2. RESEARCH AND DEVELOPMENT
  • 10.4. GC 304: GENECRADLE THERAPEUTICS
    • 10.4.1. PRODUCT DESCRIPTION
    • 10.4.2. RESEARCH AND DEVELOPMENT
  • 10.5. TLC-2716: ORSOBIO INC
    • 10.5.1. PRODUCT DESCRIPTION
    • 10.5.2. RESEARCH AND DEVELOPMENT
    • 10.5.3. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 10.6. LIPISENSE: LIPIGON PHARMACEUTICALS
    • 10.6.1. PRODUCT DESCRIPTION
    • 10.6.2. RESEARCH AND DEVELOPMENT
    • 10.6.3. SAFETY AND EFFICACY

11. PRECLINICAL-STAGE PRODUCTS

  • 11.1. COMPARATIVE ANALYSIS
  • 11.2. STP125G: SIRNAOMICS
    • 11.2.1. PRODUCT DESCRIPTION
  • 11.3. IMBP 001: IMETABOLIC BIOPHARMA
    • 11.3.1. PRODUCT DESCRIPTION
    • 11.3.2. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.4. STP251G: SIRNAOMICS
    • 11.4.1. PRODUCT DESCRIPTION
  • 11.5. STP237G: SIRNAOMICS
    • 11.5.1. PRODUCT DESCRIPTION
  • 11.6. SEFA 6131: NORTHSEA THERAPEUTICS
    • 11.6.1. PRODUCT DESCRIPTION
  • 11.7. VK1430: VIKING THERAPEUTICS
    • 11.7.1. PRODUCT DESCRIPTION

12. DISCOVERY-STAGE PRODUCTS

  • 12.1. COMPARATIVE ANALYSIS
  • 12.2. ANGPTL3/8 ANTIBODY PROGRAM: KYTTARO
    • 12.2.1. PRODUCT DESCRIPTION
    • 12.2.2. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 12.3. IMBP 150: IMETABOLIC BIOPHARMA
    • 12.3.1. PRODUCT DESCRIPTION

13. INACTIVE PRODUCTS

  • 13.1. COMPARATIVE ANALYSIS

14. STRATEGIC DEVELOPMENTS

  • 14.1. MERGERS & ACQUISITIONS
  • 14.2. PARTNERSHIPS & AGREEMENTS

15. UNMET NEEDS

LIST OF TABLES

  • TABLE 1: PRIMARY (GENETIC) DISORDERS CAUSING SEVERE HTG
  • TABLE 2: TOTAL ACTIVE PRODUCTS IN HYPERTRIGLYCERIDEMIA PIPELINE
  • TABLE 3: PRODUCTS IN VARIOUS PHASES
  • TABLE 4: EVALUATION BY ROUTE OF ADMINISTRATION
  • TABLE 5: EVALUATION BY MOLECULE TYPE
  • TABLE 6: LATE-STAGE PRODUCTS (PHASE III)
  • TABLE 7: CLINICAL TRIALS DESCRIPTION: OLEZARSEN
  • TABLE 8: GENERAL DESCRIPTION: OLEZARSEN
  • TABLE 9: CLINICAL TRIALS DESCRIPTION: MND 2119
  • TABLE 10: GENERAL DESCRIPTION: MND 2119
  • TABLE 11: CLINICAL TRIALS DESCRIPTION: PEGOZAFERMIN
  • TABLE 12: GENERAL DESCRIPTION: PEGOZAFERMIN
  • TABLE 13: MID-STAGE PRODUCTS (PHASE II)
  • TABLE 14: CLINICAL TRIALS DESCRIPTION: PLOZASIRAN
  • TABLE 15: GENERAL DESCRIPTION: PLOZASIRAN
  • TABLE 16: CLINICAL TRIALS DESCRIPTION: EVINACUMAB
  • TABLE 17: GENERAL DESCRIPTION: EVINACUMAB
  • TABLE 18: CLINICAL TRIALS DESCRIPTION: SEFA 1024
  • TABLE 19: GENERAL DESCRIPTION: SEFA 1024
  • TABLE 20: GENERAL DESCRIPTION: HU-6
  • TABLE 21: CLINICAL TRIALS DESCRIPTION: MAT-9001
  • TABLE 22: GENERAL DESCRIPTION: MAT-9001
  • TABLE 23: CLINICAL TRIALS DESCRIPTION: MN-001
  • TABLE 24: GENERAL DESCRIPTION: MN-001
  • TABLE 25: CLINICAL TRIALS DESCRIPTION: INV-202
  • TABLE 26: GENERAL DESCRIPTION: INV-202
  • TABLE 27: GENERAL DESCRIPTION: HTD1801
  • TABLE 28: GENERAL DESCRIPTION: MET-3
  • TABLE 29: EARLY-STAGE PRODUCTS (PHASE I/II)
  • TABLE 30: CLINICAL TRIALS DESCRIPTION: MAR001
  • TABLE 31: GENERAL DESCRIPTION: MAR001
  • TABLE 32: EARLY-STAGE PRODUCTS (PHASE I)
  • TABLE 33: CLINICAL TRIALS DESCRIPTION: LY3875383
  • TABLE 34: GENERAL DESCRIPTION: LY3875383
  • TABLE 35: CLINICAL TRIALS DESCRIPTION: VSA003
  • TABLE 36: GENERAL DESCRIPTION: VSA003
  • TABLE 37: CLINICAL TRIALS DESCRIPTION: GC304
  • TABLE 38: GENERAL DESCRIPTION: GC304
  • TABLE 39: CLINICAL TRIALS DESCRIPTION: TLC-2716
  • TABLE 40: GENERAL DESCRIPTION: TLC-2716
  • TABLE 41: GENERAL DESCRIPTION: LIPISENSE
  • TABLE 42: PRECLINICAL-STAGE PRODUCTS
  • TABLE 43: GENERAL DESCRIPTION: STP125G
  • TABLE 44: GENERAL DESCRIPTION: IMBP 001
  • TABLE 45: GENERAL DESCRIPTION: STP251G
  • TABLE 46: GENERAL DESCRIPTION: STP237G
  • TABLE 47: GENERAL DESCRIPTION: SEFA 6131
  • TABLE 48: GENERAL DESCRIPTION: VK1430
  • TABLE 49: DISCOVERY-STAGE PRODUCTS
  • TABLE 50: GENERAL DESCRIPTION: ANGPTL3/8 ANTIBODY PROGRAM
  • TABLE 51: GENERAL DESCRIPTION: IMBP 150
  • TABLE 52: INACTIVE-STAGE PRODUCTS
  • TABLE 53: LIST OF MERGERS & ACQUISITIONS
  • TABLE 54: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

  • FIGURE 1: CLASSIFICATION OF HTG BASED ON SERUM TG LEVEL
  • FIGURE 2: KEY STEPS INVOLVED IN THE METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
  • FIGURE 3: METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS (TGRL)
  • FIGURE 4: CAUSES OF HTG
  • FIGURE 5: THE INTERTWINED CONTRIBUTING FACTORS AND CLOSE INTERACTIONS BETWEEN HTG, TYPE II DIABETES, AND ACUTE PANCREATITIS
  • FIGURE 6: SIGNS AND SYMPTOMS OF HTG
  • FIGURE 7: PRODUCTS IN VARIOUS PHASES
  • FIGURE 8: EVALUATION BY ROUTE OF ADMINISTRATION
  • FIGURE 9: EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • FIGURE 10: EVALUATION BY MOLECULE TYPE
  • FIGURE 11: EVALUATION BY STAGE AND MOLECULE TYPE
  • FIGURE 12: LATE-STAGE PRODUCTS (PHASE III)
  • FIGURE 13: MID-STAGE PRODUCTS (PHASE II)
  • FIGURE 14: EARLY-STAGE PRODUCTS (PHASE I/II)
  • FIGURE 15: EARLY-STAGE PRODUCTS (PHASE I)
  • FIGURE 16: PRECLINICAL-STAGE PRODUCTS
  • FIGURE 17: DISCOVERY-STAGE PRODUCTS
  • FIGURE 18: INACTIVE STAGE PRODUCTS